Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | PTGES | O14684 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9665524 | 0.82 | CA1 (0.45) | MEN1KMT2AMAPTCA1SMN1; SMN2 | |
| SCHEMBL12890626 | 0.78 | ALDH1A1 (0.36) | MEN1KMT2AMAPTGRIA1CA12 | |
| SCHEMBL14200565 | 0.76 | CA1 (0.48) | GRIA1CA1CA12CA7CA14 | |
| SCHEMBL26724609 | 0.76 | CA1 (0.44) | GRIA1CA1CA12CA7CA14 | |
| SCHEMBL19996824 | 0.73 | KMT2A (0.39) | MEN1KMT2AMAPTGRIA1CA1 | |
| SCHEMBL26724611 | 0.73 | CA2 (0.48) | GRIA1CA1CA12CA7CA14 | |
| SCHEMBL272858 | 0.72 | TDP1 (0.36) | SMN1; SMN2 | |
| SCHEMBL777392 | 0.72 | CA12 (0.39) | MEN1KMT2AGRIA1CA1CA12 | |
| SCHEMBL23833903 | 0.72 | MEN1 (0.39) | MEN1KMT2AMAPTCA1SMN1; SMN2 | |
| SCHEMBL20079220 | 0.71 | EPHX1 (0.50) | MEN1KMT2AGRIA1CA1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024100139-A1 | USE OF IFN-I ACTIVITY AS A BIOMARKER FOR TLR INHIBITOR TREATMENT | MERCK PATENT GMBH (DE) | 2024-05-16 | — | — | WO | disclosed |
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300940-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | MEN1 4681/4885KMT2A 1065/4885MAPT 4291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.